BEAM (Beam Therapeutics) EBIT per Share : $-5.05 (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Beam Therapeutics EBIT per Share?

Beam Therapeutics's EBIT per Share for the three months ended in Dec. 2024 was $-1.21. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-5.05.

During the past 3 years, the average EBIT per Share Growth Rate was 6.20% per year. During the past 5 years, the average EBIT per Share Growth Rate was -14.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Beam Therapeutics's EBIT per Share or its related term are showing as below:

BEAM' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -67.4 Med: -18.35 Max: 7
Current: 6.2

During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Beam Therapeutics was 7.00% per year. The lowest was -67.40% per year. And the median was -18.35% per year.

BEAM's 3-Year EBIT Growth Rate is ranked worse than
51.98% of 1235 companies
in the Biotechnology industry
Industry Median: 8 vs BEAM: 6.20

Beam Therapeutics's EBIT for the three months ended in Dec. 2024 was $-100.04 Mil.

Beam Therapeutics EBIT per Share Historical Data

The historical data trend for Beam Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beam Therapeutics EBIT per Share Chart

Beam Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT per Share

Get a 7-Day Free Trial

-2.84

-6.11

-4.83

-2.29

-5.05

Beam Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT per Share	Get a 7-Day Free Trial															1.64	-1.28	-1.27	-1.29	-1.21

Beam Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Beam Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-415.568	/	82.313
=	-5.05

Beam Therapeutics's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

	EBIT per Share		(Q: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-100.037	/	82.828
=	-1.21

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.05

Beam Therapeutics (NAS:BEAM) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Beam Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Beam Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Beam Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beam Therapeutics Inc (NAS:BEAM) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

BEAM:Mexico

Address

238 Main Street, Cambridge, MA, USA, 02142

Website

https://www.beamtx.com

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Executives

Amy Simon	officer: Chief Medical Officer	BEAM THERAPEUTICS, INC., 238 MAIN STREET, 9TH FL., CAMBRIDGE MA 02142
Christine Bellon	officer: Chief Legal Officer	BEAM THERAPEUTICS, INC., 238 MAIN STREET, 9TH FL., CAMBRIDGE MA 02142
John M. Evans	director, officer: CEO	C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Giuseppe Ciaramella	officer: President & CSO	C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Terry-ann Burrell	officer: CFO	C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Fmr Llc	10 percent owner, other: See Remark 1	245 SUMMER STREET, BOSTON MA 02210
John Maraganore	director	75 SIDNEY ST, CAMBRIDGE MA 02139
Graham K Cooper	director	C/O RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Kathleen E Walsh	director	C/O LIFEMD, INC., 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Arch Venture Fund Ix Overage, L.p.	10 percent owner	8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631
Stephen C Knight	director	C/O EPIX MEDICAL INC, 71 ROGERS ST, CAMBRIDGE MA 02142
Mark Fishman	director	C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Arch Venture Partners Ix, Llc	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Keith Crandell	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Ix, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631